These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16586388)

  • 1. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge.
    Taylor DN; McKenzie R; Durbin A; Carpenter C; Atzinger CB; Haake R; Bourgeois AL
    Clin Infect Dis; 2006 May; 42(9):1283-8. PubMed ID: 16586388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge.
    Tacket CO; Binion SB; Bostwick E; Losonsky G; Roy MJ; Edelman R
    Am J Trop Med Hyg; 1992 Sep; 47(3):276-83. PubMed ID: 1524140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
    EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.
    Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB
    Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
    Taylor DN; McKenzie R; Durbin A; Carpenter C; Haake R; Bourgeois AL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1179-81. PubMed ID: 18086855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.
    Garey KW; Ghantoji SS; Shah DN; Habib M; Arora V; Jiang ZD; DuPont HL
    J Antimicrob Chemother; 2011 Dec; 66(12):2850-5. PubMed ID: 21948965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.
    Taylor DN; Bourgeois AL; Ericsson CD; Steffen R; Jiang ZD; Halpern J; Haake R; Dupont HL
    Am J Trop Med Hyg; 2006 Jun; 74(6):1060-6. PubMed ID: 16760520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of travelers' diarrhea with rifaximin on various continents.
    Steffen R; Sack DA; Riopel L; Jiang ZD; Stürchler M; Ericsson CD; Lowe B; Waiyaki P; White M; DuPont HL
    Am J Gastroenterol; 2003 May; 98(5):1073-8. PubMed ID: 12809830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxycycline prophylaxis for shigellosis.
    Ben-Yehuda O; Cohen D; Alkan M; Greenbaum A; Jelin N; Steinherz R
    Arch Intern Med; 1990 Jan; 150(1):209-12. PubMed ID: 2404480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea.
    DuPont HL; Ericsson CD; Mathewson JJ; Palazzini E; DuPont MW; Jiang ZD; Mosavi A; de la Cabada FJ
    Digestion; 1998; 59(6):708-14. PubMed ID: 9813398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.
    Kotloff KL; Nataro JP; Losonsky GA; Wasserman SS; Hale TL; Taylor DN; Sadoff JC; Levine MM
    Vaccine; 1995 Nov; 13(16):1488-94. PubMed ID: 8578831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.
    Prantera C; Lochs H; Campieri M; Scribano ML; Sturniolo GC; Castiglione F; Cottone M
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1117-25. PubMed ID: 16611272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rifaximin for the prevention of travelers' diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey.
    Armstrong AW; Ulukan S; Weiner M; Mostafa M; Shaheen H; Nakhla I; Tribble DR; Riddle MS
    J Travel Med; 2010; 17(6):392-4. PubMed ID: 21050319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.
    Tribble D; Kaminski R; Cantrell J; Nelson M; Porter C; Baqar S; Williams C; Arora R; Saunders J; Ananthakrishnan M; Sanders J; Zaucha G; Turbyfill R; Oaks E
    Vaccine; 2010 Aug; 28(37):6076-85. PubMed ID: 20619378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifaximin treatment of pathogen-negative travelers' diarrhea.
    DuPont HL; Haake R; Taylor DN; Ericsson CD; Jiang ZD; Okhuysen PC; Steffen R
    J Travel Med; 2007; 14(1):16-9. PubMed ID: 17241249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zanger P; Nurjadi D; Gabor J; Gaile M; Kremsner PG
    Lancet Infect Dis; 2013 Nov; 13(11):946-54. PubMed ID: 24012319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
    Launay O; Sadorge C; Jolly N; Poirier B; Béchet S; van der Vliet D; Seffer V; Fenner N; Dowling K; Giemza R; Johnson J; Ndiaye A; Vray M; Sansonetti P; Morand P; Poyart C; Lewis D; Gougeon ML
    Vaccine; 2009 Feb; 27(8):1184-91. PubMed ID: 19135496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone.
    Dupont HL; Jiang ZD; Belkind-Gerson J; Okhuysen PC; Ericsson CD; Ke S; Huang DB; Dupont MW; Adachi JA; De La Cabada FJ; Taylor DN; Jaini S; Martinez Sandoval F
    Clin Gastroenterol Hepatol; 2007 Apr; 5(4):451-6. PubMed ID: 17382603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers' diarrhea in Mexico during the dry season.
    Flores J; Dupont HL; Jiang ZD; Okhuysen PC; Melendez-Romero JH; Gonzalez-Estrada A; Carrillo I; Paredes M
    J Travel Med; 2011; 18(5):333-6. PubMed ID: 21896097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.
    Kotloff KL; Pasetti MF; Barry EM; Nataro JP; Wasserman SS; Sztein MB; Picking WD; Levine MM
    J Infect Dis; 2004 Nov; 190(10):1745-54. PubMed ID: 15499528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.